Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 18 of 103 for:    Recruiting, Not yet recruiting, Available Studies | (idiopathic pulmonary fibrosis)

Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04019080
Recruitment Status : Recruiting
First Posted : July 15, 2019
Last Update Posted : July 15, 2019
Sponsor:
Information provided by (Responsible Party):
Magnus Skold, Karolinska University Hospital

Brief Summary:
The objective of the current research project is, by using high quality Swedish registry data, to evaluate use, tolerance and effect of anti-fibrotic drugs in IPF-patients. Secondary study objectives are to determine the clinical profile, determinants of treatment adherence, long-term safety and to describe the patient journey from the first sign of disease to end of treatment.

Condition or disease Intervention/treatment
Idiopathic Pulmonary Fibrosis Other: Anti-fibrostic drugs

Layout table for study information
Study Type : Observational
Estimated Enrollment : 400 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Real-Life Use of Anti-fibrotic Drugs in Patients With Idiopathic Pulmonary Fibrosis in Sweden
Actual Study Start Date : January 1, 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021



Intervention Details:
  • Other: Anti-fibrostic drugs
    The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden


Primary Outcome Measures :
  1. Anti-fibrotic drugs among the patients recorded in the Swedish IPF-registry [ Time Frame: 2014-2020 ]
    The use of anti-fibrostic drugs



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with idiopathic pulmonary fibrosis included in the Swedish IPF-registry
Criteria

Inclusion Criteria:

  • All subjects included in the Swedish IPF-registry

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04019080


Contacts
Layout table for location contacts
Contact: Carlson, RN +46737121597 lisa.carlson@sll.se
Contact: Sköld, Prof magnus.skold@ki.se

Locations
Layout table for location information
Sweden
Karolinska University Hospital Recruiting
Stockholm, Sweden
Contact: Carlson, RN    +46737121597    lisa.carlson@sll.se   
Contact: Sköld, Prof       magnus.skold@ki.se   
Sponsors and Collaborators
Karolinska University Hospital

Layout table for additonal information
Responsible Party: Magnus Skold, Professor, Senior consultant, Karolinska University Hospital
ClinicalTrials.gov Identifier: NCT04019080     History of Changes
Other Study ID Numbers: 180293
First Posted: July 15, 2019    Key Record Dates
Last Update Posted: July 15, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial